The Diagnosis and Treatment of Autoimmune Encephalitis

Eric Lancaster
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA

Autoimmune encephalitis causes subacute deficits of memory and cognition, often followed by suppressed level of consciousness or coma. A careful history and examination may show early clues to particular autoimmune causes, such as neuromyotonia, hyperekplexia, psychosis, dystonia, or the presence of particular tumors. Ancillary testing with MRI and EEG may be helpful for excluding other causes, managing seizures, and, rarely, for identifying characteristic findings. Appropriate autoantibody testing can confirm specific diagnoses, although this is often done in parallel with exclusion of infectious and other causes. Autoimmune encephalitis may be divided into several groups of diseases: those with pathogenic antibodies to cell surface proteins, those with antibodies to intracellular synaptic proteins, T-cell diseases associated with antibodies to intracellular antigens, and those associated with other autoimmune disorders. Many forms of autoimmune encephalitis are paraneoplastic, and each of these conveys a distinct risk profile for various tumors. Tumor screening and, if necessary, treatment is essential to proper management. Most forms of autoimmune encephalitis respond to immune therapies, although powerful immune suppression for weeks or months may be needed in difficult cases. Autoimmune encephalitis may relapse, so follow-up care is important.

Key Words autoimmune, antibody, paraneoplastic, encephalitis, anti-NMDAR encephalitis.

INTRODUCTION

Autoimmune encephalitis is a difficult clinical diagnosis due to the similarities in the clinical, imaging and laboratory findings of many forms of autoimmune and infectious encephalitis. Patients generally have impaired memory and cognition over a period of days or weeks. There may be clues to specific causes on history of physical examination, but often these specific signs are absent. A broad approach to testing for infectious diseases and various neuronal autoantibodies can lead to the correct diagnosis. If a clear autoimmune cause for the symptoms is established, treatment usually involves escalating immune therapies. The process of caring for these patients requires patience and repeated evaluations to determine the proper degree of immune therapy needed at any given time.

SUBTYPES AND PATHOPHYSIOLOGY OF AUTOIMMUNE ENCEPHALITIS

Autoimmune encephalitis involves several types of diseases with different pathophysiology. Understanding the pathophysiology of these diseases is helpful in using diagnostic testing and choosing appropriate therapies. The first group includes the classic paraneoplastic disorders associated with antibodies to intracellular antigens, such as anti-Hu. These disorders are strongly cancer associated and involve T-cell responses targeting neu...
Autoimmune encephalitis can manifest with several distinct syndromes, complicating its recognition. The classical presentation of encephalitis consists of a subacute (days to a few weeks) progressive decrease in the level of consciousness, often with fluctuations, and altered cognition. Memory, especially retention of new information, may be impaired early in the clinical course. Patients may progress to coma. While many cases of autoimmune encephalitis are indistinguishable from each other or viral encephalitis, there may be clues to specific autoimmune etiologies (Table 1).

Psychiatric manifestations are common early in the course of autoimmune encephalitis. These may include psychosis, aggression, inappropriate sexual behaviors, panic attacks, compulsive behaviors, euphoria or fear. Symptoms may fluctuate rapidly. Although this presentation is well known for anti-NMDAR encephalitis, 1 anti-AMPA and anti-GABA-B-R both may have prominent early psychiatric manifestations 2 (Overall, anti-NMDAR encephalitis is more common and should be suspected first, especially in young adults and children, but they could each cause this presentation across a wide range of ages).

Abnormal movements may be the presenting symptom in several types of autoimmune encephalitis. These include anti-NMDAR encephalitis, where movement symptoms may occur early in the disease course, especially in children, who generally have more motor symptoms and fewer psychiatric symptoms than adults. 3 These may resemble dystonia or chorea, with writhing and fixed abnormal postures of the limbs. In adults with anti-NMDAR encephalitis, writhing movements of the face and limbs may be most prominent in the comatose phases of the illness. GAD65 and GlyR autoimmunity may present with stiff person syndrome (SPS) or progressive encephalomyelitis with rigidity and myoclonus.
certain types of autoimmune encephalitis may precede or follow neuromuscular manifestations, particularly acquired neuromyotonia (Isaac syndrome). Isaacs syndrome presents with muscle spasms, cramps and fasciculations due to peripheral nerve hyper-excitability. Morvan syndrome (Morvan's fibrillary chorea) consists of peripheral nerve hyper-excitability with encephalitis and severe insomnia. Some cases of Isaacs syndrome are associated with autoantibodies to Caspr2 or other, often undefined, members of the voltage-gated potassium channel (VGKC) complex. Caspr2 antibodies are even more likely in patients with Morvan syndrome, especially patients with thymoma, who may have multiple autoimmune disorders during their disease course. Encephalitis with these neuromuscular manifestations (myasthenia gravis, neuromyotonia) therefore suggests a specific autoimmune etiology.

As discussed below, most of the autoimmune causes of encephalitis are paraneoplastic, each conveying a risk profile for various tumors. Detecting particular tumors may therefore also suggest particular autoimmune causes. For instance, the likelihood of anti-NMDAR encephalitis is increased in a young woman with ovarian teratoma, and the likelihood of anti-DNER is higher in patients with cerebellar degeneration and Hodgkin lymphoma.

**EXCLUSION OF OTHER AUTOIMMUNE DISORDERS**

In addition to the antibody-mediated and paraneoplastic forms of encephalitis, there are other autoimmune diseases that may present with encephalitis. In the case of ADEM, encephalitis is a common presentation. The characteristic brain lesions, and sometimes involvement of the optic nerves or spinal cord, are an important clue to diagnosis.

Multiple sclerosis (MS) is generally easier to distinguish from autoimmune encephalitis due to more focal symptoms and characteristic brain imaging findings.

Lupus may affect diverse areas of the nervous system, causing neuropa thy, vasculitis, myelitis, venous sinus thrombosis, stroke, and other manifestations. Neuropsychiatric lupus may manifest with seizures, psychosis, or neurovascular disease. These manifestations are most common with severe disease affected other organ systems such as the gastrointestinal, renal and hematological systems. In one large series, one forth of deaths from lupus were related to CNS involvement and 16% were due to CNS infection, suggesting vigilance for both autoimmune and infectious encephalitis is warranted for these patients.

Vasculitis affecting the CNS may rarely present with symptoms resembling encephalitis. When this is suspected, im-
aging of the cerebral vessels, search for other evidence of vasculitis (such as serologies for lupus and other rheumatologic diseases) may be useful.

Bickerstaff encephalitis and Miller Fisher syndrome enter into the differential diagnosis of autoimmune encephalitis due to the presence of altered mental status and/or cranial neuropathies. These diseases may at first resemble the brain-stem syndrome associated with anti-Ri, but the loss of reflexes is an important clue suggesting Miller Fisher syndrome. Detection of the GQ1b antibody may be helpful in securing these diagnoses.\(^7\)

**EXCLUSION OF INFECTIOUS CAUSES**

It is typical for patients with autoimmune encephalitis to have testing for various infectious etiologies and they are frequently covered with antibiotic and/or antiviral therapies (such as acyclovir) empirically as infectious causes are excluded. Some of the relevant risk factors for various causes of encephalitis are listed in Table 2 and the major infections are listed in Table 3.

Most cases of infectious encephalitis are viral. In the USA, leading viral infections include are HSV, VZV, enterovirus, and West Nile virus (WNV).\(^{18}\) Japanese encephalitis (JE) was once the leading cause of viral encephalitis in East Asia, but has declined dramatically in Korea and other nations due to successful vaccination programs.\(^{19}\) Bacterial causes include listeria, atypical presentations of streptococcus, syphilis, Lyme disease, and tuberculosis. Fungal causes such as Cryptococcus or aspergillus are particularly likely in immunocompromised patients.

A detailed travel and exposure history is essential. For instance, West Nile encephalitis has been reported only once in Korea, in a patient who had recently traveled to Guinea.\(^{20}\) Travel to areas endemic for malaria or Lyme disease may be similarly relevant. Exposure to persons with tuberculosis or other infectious agents may be a clue to diagnosis.

Since the risk of various infections depends on the status of the immune system, it is important to know patients’ HIV status and consider whether other medical conditions (transplantation, cancer) may have weakened immunity. Certain types of tumors, such as lymphomas, may weaken the immune system and also increase the risk of paraneoplastic/autoimmune diseases. A detailed review of encephalitis in immunocompromised patients highlighted HSV and VZV as leading causes, along with a host of rarer entities.\(^{21}\) Infections have been transferred by the organ donor to an organ transplant recipient, including rubies, LCMV, West Nile, CMV, and EBV;\(^{22}\) these infections are a consideration in encephalitis in the weeks after transplantation.

Human herpesvirus 6 (HHV-6), and less often HHV-7, may cause encephalitis and their reactivation may be an important cause of encephalitis in transplant patients.\(^{21-25}\) HHV-6 and HHV-7 are diagnosed by PCR, although this may not be positive initially.\(^{26}\) There are no approved treatments, but ganciclovir, foscarnet, and cidofovir have been used.\(^{27}\) HHV-6 may be more likely in cases whether the donor and/or recipient of a stem cell transplant carry a particular HLA type (HLA-B*40:06).\(^{28}\)

Due to the diversity of potential infections, using a separate test for each pathogen may not be practical. To address this issue, advanced genetic techniques (e.g., metagenomic deep sequencing of cerebrospinal fluid) have been proposed to screen for thousands of pathogens rapidly and efficiently. Early successes with this approach have included diagnosing cases of encephalitis due to leptospirosis, neurotropic astrovirus infection, Balamuthia mandrillaris, and squirrel bornavirus.\(^{29-32}\) This approach should assume a wider role in diagnosing unusual CNS infections in the coming years.

Cerebellitis may occur as an infectious or post-infectious phenomenon. Leading viral causes include VZV, JC virus, influenza, EBV, and enterovirus. Numerous other bacterial, fungal, malignant, and other causes have also been reported.\(^{33}\)

**EXCLUSION OF OTHER MEDICAL CAUSES**

Wernicke encephalitis, due to thiamine deficiency, is most recognized in alcoholics but may also affect patients with gastric bypass or other causes of insufficient nutrition.\(^{34}\) A history of weeks to months of rapid weight loss is common.
in the later group, who do not have alcohol as a supplemental source of calories (The complex nutritional deficiencies after gastric surgery may present with several distinct syndromes. Of greatest relevance to this review, Wernicke encephalitis may occur along with or following an acute painful lower-extremity-predominant neuropathy.). Prompt and thorough repletion with thiamine, often along with other nutrients, may be life saving and should not wait on laboratory confirmation of the diagnosis.

Intoxications such as a neuroleptic malignant syndrome and serotonin syndrome may often present with similarities to autoimmune encephalitis. Conversely, patients with anti-NMDAR encephalitis may develop psychosis as an initial symptom and be treated with neuroleptics, then later show catatonia, rigidity, autonomic instability and altered level of consciousness; this pattern of findings may be mistaken for neuroleptic malignant syndrome. Autoimmune encephalitis therefore should enter into the differential diagnosis of any case of suspected neuroleptic malignant syndrome (Patients with anti-NMDAR encephalitis may be particularly sensitive to strong dopamine antagonists, and our group attempts to avoid using these medications).

**Table 3. Infectious causes of encephalitis**

| Pathogen                       | Test         | Notes                                                                 |
|--------------------------------|--------------|----------------------------------------------------------------------|
| HSV                            | PCR          | A common cause in both healthy and immune-compromised patients, with particular predilection for the temporal lobes<sup>40</sup> Specific anti-viral therapy may be life-saving Rare cases of secondary anti-NMDAR encephalitis afterwards<sup>41</sup> |
| CMV                            | PCR          |                                                                      |
| VZV                            | PCR          |                                                                      |
| JE                             | PCR          | Once a leading cause in East Asia, but declining due to vaccination programs |
| Enterovirus                    | PCR          | Other, non-polio, strains may also be neurotropic and it is a relatively common cause of encephalitis |
| HHV6                           | PCR          | Important cause in transplant patients 1% of persons have HHV-6 in their genome, so PCR test can be misleading |
| HHV7                           | PCR          | Rare cause in immune compromised patients                           |
| Neuroborreliosis (Lyme disease)| Serology     | 10–15% of untreated patients have neurological symptoms Manifestations include meningitis, encephalitis, radiculitis, cranial neuritis, and peripheral neuropathy<sup>47</sup> |
| WNV (West Nile)                | PCR, Serology| Widely distributed mosquito-born flavivirus Most infections asymptomatic or minimally symptomatic Encephalitis is the most common presentation, followed by meningitis and flaccid paralysis<sup>48</sup> |
| Syphilis                       | Serologies   | Most cases are sexually transmitted. Neurological symptoms may occur years or decades after exposure. Manifestations are protean |
| Cryptococcus                   | Latex agglutination antigen test, culture | More often presents with meningitis in patients with AIDS and other immune-compromised states CSF opening pressure may be marked elevated |
| Aspergillus fumigatus          | Culture, biopsy, antigen ELISA and other methods | Disseminated CNS aspergillosus is mostly in immune compromised (transplant patients), and pathology usually involves basal ganglia and/or thalami<sup>49</sup> |
| Mucor                          | Culture, biopsy (ideally for nasal involvement) | May affect both immunocompromised and immune intact persons Prognosis is grim |
| Tuberculosis                   | Chest X-ray, PPD, Serology | In one study the second most common cause of infectious temporal lobe encephalitis behind HSV<sup>46</sup> May also present with Rhombencephalitis |
| Listeria                       | Culture      | Rhombencephalitis and meningitis are the two main manifestations |
| Streptococcus                  | Culture      |                                                                      |
| Toxoplasmosis                  | Serology     | Classically, a common cause of brain lesions in patients with AIDS |

CNS: central nervous system.
Autoimmune Encephalitis

Lymphoma or carcinomatous meningitis may present similarly to autoimmune encephalitis. Particularly, symptoms may have a subacute onset and involve multiple cranial neuropathies. Both may occur in patients with or without known tumors. Repeating CSF cytology, awareness of known tumors, and screening for malignancy may all help lead to recognition of these causes.

DIAGNOSTIC APPROACHES

**Antibody testing**

Autoantibody testing is extremely important for the proper diagnosis of autoimmune encephalitis. However, the tests have complexities that require consideration, and taking certain test results as conclusive evidence of autoimmune encephalitis can be a mistake.

Commercial tests for autoantibodies to NMDAR, LGI1, Caspr2, AMPAR (GluR1, GluR2 subunits), and GABA-B-R are widely available. Newer cell surface antigens like GABA-A-R and DPPX are more difficult to test clinically. The synaptic intracellular antigens GAD65 and Amphiphysin, as well as the conventional intracellular “onconeuronal” antibodies are widely available. In the correct clinical context, these antibodies can be diagnostic. But there are complexities to interpreting some of these tests.

NMDAR and other cell surface antibody tests are most sensitive and specific with CSF. Serum may offer a low false positive rate and a higher false negative rate. Pathogenic cell surface or synaptic autoantibodies are IgG responses. NMDAR IgM and IgA responses have been reported in patients with schizophrenia and other psychiatric disease but also in up to 10% of normal controls; these IgM and IgA responses have no established role in diagnosing autoimmune encephalitis. Conversely, the types of IgG responses associated with anti-NMDAR encephalitis are not found in patients with schizophrenia.

The availability of titers for NMDAR antibodies has led some practitioners to attempt to use these titers to guide treatment. However, titers have limited clinical utility for several reasons: 1) absolute titers provide little information on disease severity, 2) titers in serum do not correlate reliably with disease status, and 3) CSF titers correlate only roughly to disease status within a given patient using side-by-side comparisons of multiple samples. Therefore, it is better to focus on the clinical status of the patient and not changes in antibody titer during the early phases of the illness. NMDAR CSF titers may be compared to earlier samples side-by-side in assessing whether clinical worsening represents a true relapse, but this is only rarely helpful.

Caspr2 and LGI1 each associate with VGKCs. The VGKC antibody test is based on immunoprecipitation of a complex of protein containing VGKCs, LGII, Caspr2 and other proteins. The VGKC RIA was created 15 years before the recognition of LGI1 or Caspr2 antibodies, and patients with these antibodies were thought, incorrectly, to actually have antibodies to potassium channel subunits themselves. The VGKC test may still detect patients with LGI1 or Caspr2 immunity, but low titer serum positive results have uncertain clinical significance. For instance, Paterson et al. reported that only 4 of 32 patients with low titer VGKC results (100–400 pM) actually had an autoimmune disorder. Thus a low titer serum VGKC result without corresponding evidence of LGI1 or Caspr2 antibodies, ideally in the CSF, should not be taken as definitive evidence of autoimmune encephalitis.

GAD65 antibodies have diverse clinical correlates, including SPS, cerebellar degeneration, epilepsy, and type 1 diabetes. In the context of encephalitis, especially with epilepsy, a CSF GAD65 response is evidence of an autoimmune etiology. However, GAD65 may co-exist with other autoantibodies, such as GABA-B-R, so may or may not represent the most relevant pathophysiological mechanism in some patients with multiple antibodies. In addition, low titer GAD65 serum responses may not be specific for a neurological disorder, and GAD65 serum antibodies provide little additional information in a patient with known type 1 diabetes. Conversely, I have observed patients who develop type 1 diabetes after the onset of their neurological syndrome in the context of GAD65 antibodies. Testing CSF of these patients for GAD65 and a panel of other autoantibodies may be informative in these cases.

Hashimoto’s encephalopathy is generally defined as encephalopathy associated with thyroid autoantibodies that respond to steroids or other immune therapies. It has not been shown that thyroid antibodies can directly affect the brain, and the abnormalities in thyroid hormone levels are generally too mild to explain the brain disease. Some of these cases are due to other autoantibodies, such as to the NMDAR or GABA-B-R, but the true cause of most cases is unknown. Thyroid antibodies are therefore sometime tested in patients with autoimmune encephalitis. Finding thyroid antibodies should prompt a careful search for responsive other autoantibodies to brain that would provide a more convincing explanation of the symptoms. But if these antibodies are not found immune therapy should be considered.

**Imaging**

Brain MRI in patients with NMDAR, AMPAR, LGI1, Caspr2, and GABA-B antibodies may be normal or show increased T2 signal, especially in the medial temporal lobes.
This pattern is similar to the findings seen in HSV encephalitis, where 95% of patients have abnormalities on MRI, or other viral causes of encephalitis. Tuberculosis, Syphilis, or other infections may present similarly. Autoantibodies to DPPX or GABA-A may have less characteristic findings. Brain MRI therefore does not distinguish between infectious and autoimmune causes, and a normal brain MRI does not exclude these causes.

Advanced brain imaging with PET or SPECT has shown diverse areas of regional hyper- or hypo-metabolism in patients with NMDAR, LGI1, Caspr2 or other autoantibodies. These studies have not reached the point where any particular form of encephalitis can be distinguished from another, so I do not generally rely on these studies to rule in or rule out autoimmune causes in my practice.

EEG

EEG is useful in patients with autoimmune or infectious encephalitis for excluding subclinical seizures, for prognosis, and sometimes for suggesting particular diagnoses. In patients with HSV encephalitis, EEG may predict prognosis in addition to helping exclude non-convulsive seizures; normal EEG correlates with good outcomes independent of other prognostic factors.

Seizures may occur at any point during the disease course of anti-NMDAR encephalitis, including at presentation. The extreme delta brush pattern may be observed in patients with anti-NMDAR encephalitis, most often in patients who are comatose. This distinctive EEG pattern should prompt testing for NMDAR antibodies. Patients with anti-NMDAR encephalitis and other forms of autoimmune encephalitis may also have prolonged periods of unresponsiveness and abnormal behaviors that are not due to seizures, so in these cases prolonged EEG monitoring may be very helpful.

Status epilepticus may occur in several forms of autoimmune encephalitis. The highest risk appears to be in patients with autoantibodies to the major brain inhibitory receptors GABA-A and GABA-B. High-titer antibodies to either of these antigens conveys a risk of status, which may be refractory to the unusual treatments. Since these antibodies are both much rarer than other autoantibodies to the NMDA receptor, the status epilepticus in the setting of autoimmune encephalitis probably occurs more frequently with NMDAR antibodies overall.

LGI1 antibodies are associated with FBDS, which may present weeks or months prior to other symptoms. The clinical characteristics of these seizures are distinctive, involving rapid jerking of one side of the face and/or upper extremity. Each seizure tends to be unilateral but they may occur on both sides. Some events are simple partial and very rapid, but complex partial seizures may occur as they become more frequent. EEG may show multifocal onset seizures and other abnormalities.

In my experience, seizures in autoimmune encephalitis are associated with active disease (e.g., are unlikely to persist after remission of other symptoms of autoimmune encephalitis). These seizures may be very difficult to control with anti-seizure medications until the autoimmune disease is treated.

Biopsy

Brain biopsy generally is not used in the diagnosis of encephalitis for several reasons. Infections may be detected by PCR, culture or other less invasive methods. The well-defined autoantibody causes typically have antibody tests that are much less invasive and much more definitive. In addition, the results of biopsy are generally not definitive for a particular autoimmune etiology. Overall, the clinical impact of biopsy done for suspected encephalitis is low, with only about 8% of cases having clear benefit.

Cancer screening

Paraneoplastic disorders are, in general, autoimmune disorders that are triggered by tumors. In many cases the target antigen is expressed by tumor tissue, such as HuD proteins in small cell lung cancer and NMDARs in ovarian teratoma. In these patients it is likely that presentation of the antigen in the context of the tumor triggers the autoimmune response. However, other patients without tumors may have an identical clinical syndrome and immunological response (antibody specificity, neuropathology, etc.).

It is important to detect tumors promptly for several reasons. 1) Treating the relevant tumor is thought to be helpful for treating the autoimmune disorder. 2) Tumor therapy and immune therapy may need to be given simultaneously and in a coordinated fashion. 3) Treatment with steroids, rituximab, or cyclophosphamide could complicate tumor diagnosis in the case of tumors like lymphoma.

In the case of “onconeural” antibodies to intracellular antigens such as Hu, the antibodies may occur more commonly in cancer patients than in patients with autoimmune disease. For instance low titer serum Hu responses are common in small cell lung cancer patients without the anti-Hu neurological syndromes. For this reason, finding such an antibody should prompt a careful evaluation for tumor even if there is not a corresponding autoimmune disease. For instance, an elderly diabetic smoker may be tested (inappropriately) for anti-Hu to evaluate a mild slowly progressive small fiber neuropathy. In this case, a low titer serum Hu antibody would be far less likely to explain the neuropathy than the diabetes, but should nonetheless prompt
screening for lung cancer. Similarly, a patient with known lung cancer may develop neuropathy after chemotherapy; finding Hu antibodies in such a patient should not be taken as definitive evidence of a paraneoplastic disorder.

Cell surface/synaptic antibodies are generally found in the spinal fluid only in patients with the relevant neurological disorder and are not found incidentally. Each of these antibodies has a cancer risk profile that should inform the search for tumors.

The testing strategy depends on the specific autoantibody and/or clinical syndrome. Where there is risk for lung cancer or other solid tumors, CT scans and PET/CT may be appropriate. In syndromes associated with ovarian teratoma, evaluation with ultrasound or pelvic MRI. In young men where Ma2 is diagnosed or suspected testicular ultrasound is important. Breast imaging with mammogram or MRI, pap smear, and pelvic imaging may be most helpful in women with anti-Yo. Screening should be broad in patients with high-risk syndromes such as cerebellar degeneration even when a particular antibody is not identified. Tumors may be very small when the neurological symptoms begin, so screening is typically done on initial presentation and repeated at increasing intervals. For instance, a young woman with anti-NMDAR encephalitis may have pelvic MRI at diagnosis, and repeated studies at 6 months, 1 year, and 2 years. A patient with DNER antibodies (conveying a 90% risk of Hodgkin lymphoma) might have PET-CT at diagnosis then close follow-up with an oncologist and repeat studies starting 3–4 months later.

**SPECIFIC TYPES OF AUTOIMMUNE ENCEPHALITIS**

**Autoantibodies to cell surface antigens**

Anti-NMDAR (N-methyl-D-aspartate receptor) encephalitis has a characteristic clinical syndrome in most patients. Symptoms of psychosis and memory impairment are commonly the initial findings with abnormal movements, seizures, and depressed level of consciousness emerging later. Patients may experience the psychotic symptoms again as they wake from coma, a phenomenon analogous to the psychotic symptoms seen after recovery from phencyclidine anesthesia (phencyclidine, also known as PCP or "angel dust", is an NMDAR antagonist developed as an anesthetic but is not used due to the high risk of psychosis). Ovarian teratoma affects many female patients of reproductive age, but other tumors (and tumors outside women of reproductive age) are rare. The response to immune therapy is generally good, particularly if the more effective treatments are used promptly. However, treatment may take many months to reach its full effects, and some patients have persistent deficits, especially in the domains of memory and cognition. The mechanisms of NMDAR antibodies have been extensively studied: these antibodies cross-link and internalize the target receptors, depleting NMDARs from synapses. The antibodies are clearly directly pathogenic; passive transfer into the brains of rodents produced neurological symptoms that correlate with reduction in surface NMDARs on neurons. Anti-LGI1 (Leucine-rich, glioma-inactivated 1) encephalitis accounts for most cases of encephalitis previously attributed to VGKC antibodies (The VGKC test, as described above, detects most LGI1 cases and also most Caspr2 cases). Myoclonus, hyponatremia, and fascio-brachial dystonic seizures are common. In some cases fascio-brachial dystonic seizures precede other symptoms of the disease by months. These seizures have characteristic appearance and respond well to immune therapy. Respiratory failure and critical illness are less common with LGI1 than NMDAR antibodies, but the course may be slower. The median age is about 60 years, significantly older than anti-NMDAR encephalitis. LGI1 is a secreted synaptic protein that organizes AMPA receptors and VGKCs at CNS synapses. LGI1 antibodies have been shown to affect AMPA receptor localization on cultured neurons, but additional mechanisms involving the localization of potassium channels are also possible. Cancers are relatively rare in this disorder, and some of these may be chance events in this older age group.

Anti-Caspr2 (contactin-associated protein-like 2) associated with encephalitis, Morvan syndrome and acquired neuromyotonia (Isaacs syndrome). The most common phenotype is Morvan syndrome, but peripheral nerve symptoms may precede or follow encephalitis by months or years. Encephalitis tends to be slower in onset than anti-NMDAR encephalitis, and responds to immune therapy but is prone to relapse with taper of immune therapy. Some patients may have thymoma and this subgroup is particularly prone to co-morbid myasthenia gravis and other autoimmunities found in thymoma patients. The median age is about 60 years, significantly older than anti-NMDAR encephalitis. Caspr2 is a cell adhesion molecule that organizes VGKCs at the juxtaparanodes of myelinated axons in the central and peripheral nervous system. It is unknown why some patients have CNS versus peripheral nerve symptoms since the antigen is the same on both types of axons.

Anti-AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor encephalitis may have psychiatric symptoms on presentation like anti-NMDAR encephalitis. AMPA receptors are a widely expressed type of glutamate ionotropic receptors used for much of the rapid excitatory transmission in the brain. There is significant risk...
of tumors of the lung, breast, and thymus in these patients. Most patients are female and they are mostly middle-aged and older.

Anti-GABA-B (γ-Aminobutyric acid B) receptor encephalitis is characterized by encephalitis with severe seizures or status epilepticus. This is logical due to the inhibitory role of the GABA-B receptor system in the brain (GABA-B receptors are important for limiting excessive neuronal activity). About half of patients have small cell lung cancer and the patients are mostly older adults. Antibodies to the GABA-B receptor may be the most common type of immune cause found in patients with lung cancer.

Anti-GABA-A (γ-Aminobutyric acid A) receptor encephalitis has been reported in children and adults. At high titer these antibodies, which target the primary inhibitory ionotropic receptor in the brain, associate with severe encephalitis with status epilepticus or epilepsy partialis continua. So far only 1 of 6 patients had a tumor, Hodgkin lymphoma, but the full cancer associations will become clearer as more cases are found.

Anti-mGluR1 (metabotropic glutamate receptor 1) have been reported in a small number of patients with paraneoplastic cerebellar degeneration. There is a high risk of Hodgkin lymphoma in these patients. Similarly, antibodies to Homer-3, which organizes mGluR1 at synapses, have been reported in a single patient.

Anti-mGluR5 (metabotropic glutamate receptor 5) have been reported in a few patients with Ophelia syndrome, a relatively mild form of encephalitis that occurs in patients with Hodgkin lymphoma. Typically the patients become confused and often seem adrift in time, as described by Carr in his original reports. Patients do not generally have the sorts of psychosis, agitation, seizures, and autonomic instability seen, for example, in patients with NMDAR antibodies. Patients improve dramatically with treatment of the lymphoma. Although mGluR1 and mGluR5 are close homologs, the antibodies do not cross react and the clinical syndromes are distinct.

Anti-DNER (delta/notch-like epidermal growth factor-related receptor) target a transmembrane protein expressed on Purkinje neurons and associate with cerebellar degeneration and a very high risk (90%) of Hodgkin lymphoma. Before the precise definition of the antigen, these antibodies were referred to as “anti-Tr” and often classified with the conventional paraneoplastic disorders. Patients should be carefully and repeated screened for Hodgkin lymphoma. Even with successful tumor treatment there is often permanent cerebellar injury.

Anti-GlyR (Glycine receptor) target the primary inhibitor ionotropic receptor in the spinal cord. Symptoms accordingly resemble strychnine toxicity: increased muscle tone, spasms, and pathologically exaggerated startle response. These antibodies should be considered in patients with SPS, especially those showing a PERM-like phenotype. There is some risk of cancer, although most patients do not have tumors.

Anti-DPPX (dipeptidyl-peptidase-like protein-6) associate with a syndrome of gastrointestinal and nervous system hyper-excitability. In addition to memory loss, seizures, and confusion, symptoms of exaggerated startle, myoclonus, rigidity and hyper-reflexia have been reported. Patients may have severe diarrhea or alternatively have constipation. A small group of these patients may have tumors such as lymphoma.

**Autoantibodies to intracellular synaptic proteins**

Anti-GAD65 (glutamic acid decarboxylase 65kd) target the synaptic isoform of the enzyme necessary to synthesize GABA. GAD65 antibodies have diverse clinical associations, including type 1 diabetes, cerebellar ataxia and SPS. In patients with the neurological symptoms a strong antibody response in the CSF is common. In the paraneoplastic context (that is, when cancer is present), GAD65 antibodies associate with diverse syndromes including encephalitis, SPS and paraneoplastic cerebellar degeneration. When cancer is present GAD65 antibodies more frequently co-existing to autoantibodies to GABA-A or GABA-B.

Anti-Amphiphysin target an intracellular protein important for recycling synaptic vesicles. The antibodies are very strongly associated with SPS in women with breast cancer. The SPS more often affects the cervical region and responds to tumor therapy and/or immune therapy.

**Autoantibodies to intracellular antigens**

Anti-Hu (ANNA-1) was the first type of onconeural antibody described. Patients with anti-Hu most often have sensory-predominant neuronopathy but may also or alternatively have cerebellar degeneration, encephalitis or encephalomyelitis. Multifocal involvement is common. The antibodies target a family of intracellular proteins. These antibodies are not directly pathogenic and do not cause disease in active immunization or passive transfer animal models. Pathology studies show CD8 positive T-cell infiltrates in affected tissues. The association with small cell lung cancer is very strong (approximately 86% in one series) and outcomes are often poor.

Anti-Ri (ANNA-2) associate with diverse syndromes including cerebellar degeneration and encephalitis. Most patients have lung or breast cancers.

ANNA-3 have only rarely been described and the clinical
features are multifocal and have a similar range as anti-Hu.  
Anti-Yo (PCA-1) are found in women with breast or ovarian cancers in more than 90% of cases. Patients usually have paraneoplastic cerebellar degeneration. Approximately half of patients die of their tumors, and tumors are often only detected after identification of the paraneoplastic disorder. There is some evidence that the antibodies may enter neurons, but other researchers think T-cell mechanisms are more likely.

PCA-2 have only rarely been reported and may associate with encephalitis or cerebellar syndromes.

Anti-CRMP-5 have diverse associations including cognitive impairment, cerebellar syndromes, abnormal movements (chorea), and cranial neuropathies. Optic neuritis has also been reported.

Anti-Ma2 (PMNA-2) are found most often in young men with germ cell tumors. Neurological symptoms could include encephalitis, cerebellar degeneration, or neuropathy. Limbic and/or brainstem syndromes may be most common.

TREATMENT APPROACHES

Treatment for suspected autoimmune encephalitis is often given empirically prior to specific antibody test results. This may include steroids and/or IVIG. If a cell-surface/synaptic antibody disorder is diagnosed, initial treatments may include IVIG, plasmapheresis, and/or steroids. Steroids may be beneficial in a range of autoimmune disorders but could potentially create problems with the diagnosis of certain disorders such as CNS lymphoma. IVIG offers an important advantage of being unlikely to make infectious encephalitis worse. Plasmapheresis is also unlikely to significantly worsen infectious encephalitis.

If a synaptic/cell-surface antibody is detected and the patient has any significant symptoms, first-line therapy should be given if it has not already been tried. In general, prompt treatment, and escalation of treatment in patients who remain ill, is associated with better outcomes. Although there are not randomized treatment trials, protocols have been proposed for anti-NMDAR encephalitis, and these approaches have been applied to other diseases in the cell-surface/synaptic autoantibody category. Our group often uses IV solutedrol (1 gram daily for 3–5 days then a taper over several weeks) and IVIg (0.4 g/kg/day for 5 days). Other groups have advocated plasmapheresis instead of IVIg, and so far there is not convincing evidence of superiority for either approach.

If the patient remains significantly impaired after first-line therapy, second-line treatments are typically used. Some groups might wait 2 weeks or longer to allow first-line therapies time to work, but our group often proceeds more quickly to second line therapy sooner is patients who are very ill, for instance comatose patients with anti-NMDAR encephalitis. Second line therapies include rituximab (often 375 mg/m² weekly for 4 weeks) or cyclophosphamide (750 mg/m² IV monthly until improvement is noted), or both. Rituximab is a monoclonal antibody targeting CD20, so plasmapheresis generally should not be done after it is administered. Rituximab depletes CD19+/CD20+ B-cells, and circulating levels of these cells typically become undetectable for several months after treatment. Due to its relatively favorable safety profile, rituximab is more often used as monotherapy in children. Rituximab is thought to be generally effective against neurological diseases where the autoantibodies are of the IgG4 subtype. Since IgG4 responses predominate in LGI1 and Caspr2 encephalitis this provides an additional theoretical support for using rituximab in those diseases. Cyclophosphamide has several important toxicities, including a risk of infertility, especially in young women who received repeated doses (The risk cumulatively increases, potentially up to 40% after 12 doses). This risk can be reduced with use of a GnRH agonist in women, or addressed with egg/sperm collection.

AUTOIMMUNE ENCEPHALITIS IN CHILDREN

Anti-NMDAR encephalitis is by far the most common type of antibody-mediated encephalitis in children. The age distribution of other types of synaptic autoimmune disorders either skews much older (the median age for LGI1 or Caspr2 antibodies is about 60 years) or the disorders are much less common (GABA-A antibodies) or both. In a study by the California encephalitis project, anti-NMDAR encephalitis was more common any single viral etiology.

Anti-NMDAR encephalitis in children may present differently than in adults. Children are more likely to have abnormal movements (chorea, incoordination) early in the disease course and also may have atypical motor symptoms such as ataxia or hemiparesis. Children more often have seizures than adults. The classic symptoms of psychosis seen in adults are less common, but behavioral regression is frequently noted. Patients may have prominent speech difficulties. Treatment strategies are similar in children and adults, but physicians may be more reluctant to use cyclophosphamide, relying more on rituximab as a second line treatment (As with adults, the optimal treatment strategies are not known). Responses to treatment are similar in children and adults, with about half failing first line therapies. Ovarian teratoma is less likely in female children before puberty, so
tumors are uncommon in young children.

**RELAPSING ENCEPHALITIS**

Patients with encephalitis may recover, completely or partially, and then experience worsening symptoms. In autoimmune encephalitis, relapse tends to follow a similar clinical course to the initial attack. In anti-NMDAR encephalitis, these relapse tend to be milder than the initial attack and manifest with confusion, worsening memory, personality change, hallucinations or new seizures (In my experience, seizures in my cases of autoimmune encephalitis remit with appropriate treatment, and new seizure should always raise concern for relapse). The risk of relapse in anti-NMDAR encephalitis in approximately 12% over two years (but continues beyond that) and is highest in untreated patients, intermediate in patients who had only first-line therapy, and lowest in patients treated with second-line therapies. Relapsed patients are usually treated with second-line therapies, possibly after first line therapies. These patients may be treated for longer periods of time with second line therapy, especially rituximab, but the optimal duration of treatment has not been established. In other types of autoimmune encephalitis, the risk of relapse is less clearly established. LG1 antibodies and Caspr2 antibodies may associate with milder encephalitis, compared with NMDAR antibodies, than is chronic or relapsing. Similar treatment strategies may be used with these antibodies.

An important recent advance has been the recognition that patients with HSV encephalitis may rarely develop anti-NMDAR encephalitis several weeks later as a post-infectious complication. In these patients CSF from the initial attack has no NMDAR antibodies with positive PCR for HSV, but CSF from the second attack now has NMDAR antibodies with negative PCR for HSV. This phenomenon may be due to exposure of CNS antigens to the immune system in the presence of a powerful infectious stimulus. Patients who worsen after infectious encephalitis should therefore be carefully evaluated for both infectious and autoimmune etiologies. Similarly, patients who have been treated for autoimmune encephalitis may be immunosuppressed and at risk for diverse infections. However, opportunistic CNS infections after autoimmune encephalitis are probably very rare compared to worsening of the autoimmune disease.

**CONCLUSIONS**

The proper diagnosis and management of autoimmune encephalitis requires an organized approach. Evaluation should begin with a detailed history and physical examination to detect clues to specific causes. A diverse range of infections should be considered, and appropriate testing should be done to exclude relevant pathogens. Ancillary testing with MRI, EEG, and lumbar puncture may further support a diagnosis of encephalitis and potentially suggest particular causes. A broad group of autoantibody tests may be used to diagnose or exclude particular autoimmune causes, but these tests are complex and not every positive result is definite evidence of an autoimmune disorder. The risk of neoplasm should always be considered during initial treatment and follow-up visits, both in terms of diagnosing serious cancers and because specific tumors may suggest particular autoimmune causes. Treatment should depend on the pathophysiology of the disorder (e.g., T-cell-mediated or antibody mediated) and the clinical situation of the patient. Patients may relapse and should receive appropriate follow-up care from a physician familiar with the diseases.

**Conflicts of Interest**

The author has no financial conflicts of interest.

**REFERENCES**

1. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol* 2011; 10:63-74.
2. Höffberger R, Titulaer MJ, Sabater L, Dome B, Rössas A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. *Neurology* 2013;81:1500-1506.
3. Armanague T, Titulaer MJ, Málaga I, Bataller L, Gabilondo I, Graus F, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. *J Pediatr* 2013; 162:850-856.e2.
4. McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. *JAMA Neurol* 2013;70:44-50.
5. Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S, Connolly S, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. *Neurology* 2008;71:1291-1292.
6. Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. *Brain* 2012;135(Pt 11):3453-3468.
7. Walker KG, Wilmshurst JM. An update on the treatment of Sydenham’s chorea: the evidence for established and evolving interventions. *Ther Adv Neurol Disord* 2010;3:301-309.
8. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. *Lancet Neurol* 2010;9:67-76.
9. Petit-Pedrol M, Armanague T, Peng X, Bataller L, Cellucci T, Davis R, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. *Lancet Neurol* 2014; 13:276-286.
10. Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede LG1 antibody limbic encephalitis. *Ann Neurol* 2011;69:892-900.
11. Isaacs H. A Syndrome of continuous muscle-fibre activity. J Neurol Neurosurg Psychiatry 1961;24:319-325.
12. Isaacs H. Continuous muscle fibre activity in an Indian male with additional evidence of terminal motor fibre abnormality. J Neurol Neurosurg Psychiatry 1967;30:126-133.
13. Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez E, et al. Investigations of casp2r, an autoantigen of encephalitis and neurotoxemia. Ann Neurol 2011;69:303-311.
14. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neurotoxemia. Brain 2010;133:2734-2748.
15. Sanna G, Piga M, Terryberry JW, Peltz MT, Giaghadu S, Satta L, et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus 2000;9:573-583.
16. Kiewrthanakul P, Sawanyawisuth K, Foocharoen C, Tiamkao S. Clinical features and predictive factors in neuropsychiatric lupus. Asian Pac J Allergy Immunol 2012;30:55-60.
17. Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 2013;84:576-583.
18. Venkatesan A. Epidemiology and outcomes of acute encephalitis. Curr Opin Neurol 2015;28:277-282.
19. Lee DW, Choe YJ, Kim JH, Song KM, Cho H, Bae GR, et al. Epidemiology of Japanese encephalitis in South Korea, 2007-2010. Int J Infect Dis 2012;16:e448-e452.
20. Hwang J, Ryu HS, Kim H, Lee SA. The first reported case of West Nile encephalitis in Korea. J Korean Med Sci 2015;30:343-345.
21. Saylor G, Thakur K, Venkatesan A. Acute encephalitis in the immunocompromised individual. Curr Opin Infect Dis 2015;28:330-336.
22. Pruitt AA. Nervous system viral infections in immunocompromised hosts. Handb Clin Neurol 2014;123:685-704.
23. Agut H, Ronnafous P, Gautheret-Dejean A. Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev 2015;28:313-335.
24. Fay AI, Noetzel MJ, Mar SS. A case of pediatric hemorrhagic brainstem encephalitis associated with HHV-7 infection. Pediatr Neurosurg 2015 [Epub ahead of print]. doi: 10.1016/j.pediatrneurosurg.2015.06.016.
25. Yamamoto S, Takahashi S, Tanaka R, Okayama A, Araki A, Katano H, et al. Human herpesvirus-6 infection-associated acute encephalopathy without skin rash. Brain Dev 2015;37:829-832.
26. Kasberg-Koniarczyk HL. Human herpesvirus-6 encephalitis after hematopoietic stem cell transplantation. J Adv Pract Oncol 2014;5:373-378.
27. Prichard MN, Whitley RJ. The development of new therapies for human herpesvirus 6. Curr Opin Virol 2014;9:148-153.
28. Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigaitubo Y, Kanamori H. Human herpesvirus-6 encephalopathy after hematopoietic stem cell transplantation and class I human leukocyte antigen. Clin Transplant 2014;28:540-545.
29. Wilson MR, Naccache SN, Saayama E, Biagtan M, Bishir H, Yu G, et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med 2014;370:2408-2417.
30. Naccache SN, Peggs KS, Mattes FM, Phadke R, Garson JA, Grant P, et al. Diagnosis of neuroinvasive astrovirosis in an immunocompromised adult with encephalitis by unbiased next-generation sequencing. Clin Infect Dis 2015;60:919-923.
31. Wilson MR, Shanbhag NM, Reid MJ, Singhal NS, Gelfand JM, Sample HA, et al. Diagnosing balamuthia mandrillaris encephalitis with metagenomic deep sequencing. Ann Neurol 2015 [Epub ahead of print]. doi: 10.1002/ana.24499.
32. Hoffmann B, Tappe D, Höper D, Herden C, Boldt A, Mawrin C, et al. A variated squirrel bornavirus associated with fatal human encephalitis. N Engl J Med 2015;373:154-162.
33. Pruitt AA. Infections of the cerebellum. Neurol Clin 2014;32:1117-1131.
34. Lallas M, Desai J. Wernicke encephalopathy in children and adolescents. World J Pediatr 2014;10:293-298.
35. Juhasz-Pocayne K, Rudnicki SA, Archer RL, Harik SI. Neurologic complications of gastric bypass surgery for morbid obesity. Neurology 2007;68:1843-1850.
36. Jearanaipal S, Sangruji T, Danchavijitr C, Danchavijitr N. Neoplastic meningitis: a retrospective review of clinical presentations, radiological and cerebrospinal fluid findings. J Med Assoc Thailand 2014;97:870-877.
37. Lancaster E, Leypoldt F, Titulaer MJ, Honnorat J, Waters PJ, Reindl M, et al. Immunoglobulin G antibodies to the N-Methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. Ann Neurol 2015;77:183.
tection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuropathy. Neurology 1991;41:1757-1764.

53. Dalmau J, Tüzün E, Wu HY, Masjuan J, Ross JS, Voloschuk A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36.

54. Moscati EH, Jain A, Peng X, Hughes EG, Dalmau J, Balice-Gordon RJ. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci 2010;32:298-309.

55. Planagumà J, Leyboldt F, Mannara F, Gutiérrez-Cuesta J, Martín-García E, Aguilar E, et al. Human N-methyl-D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015;138(PT1):94-109.

56. Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, et al. Faciobrachial dystonic seizures: the influence of immune therapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013;136(PT10):3151-3162.

57. Ohkawa T, Fukata Y, Yamasaki M, Miyazaki T, Yokoi N, Takahshima H, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013;33:18161-18174.

58. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424-434.

59. Sillevis Smitt P, Kinosita A, De Leeuw B, Moll W, Coemans M, Jaarsma D, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000;342:21-27.

60. Lancaster E, Martínez-Hernández E, Titulaer MJ, Boulou M, Weaver S, Antoine JC, et al. Antibodies to metabolic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011;77:1698-1701.

61. Carr I. The Ophelia syndrome: memory loss in Hodgkin’s disease. Lancet 1982;1:844-845.

62. de Graeff A, Maat P, Hulsboom E, van den Berg R, van den Bent M, Demmers J, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012;71:815-824.

63. Greene M, Lai Y, Baella N, Dalmau J, Lancaster E. Antibodies to Delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol 2014;71:1003-1008.

64. Bernal F, Shamsi S, Rojas I, Sanchez-Valle R, Sair A, Dalmau J, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology 2003;60:230-234.

65. Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014;137(PT8):2178-2192.

66. Gresa-Arribas N, Ariño H, Martínez-Hernández E, Petit-Pedrol M, Sabater L, Saiz A, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS One 2015;10:e0121364.

67. Ariño H, Höflberger R, Gresa-Arribas N, Martínez-Hernández E, Arangüe T, Kruer MC, et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol 2015;72:874-881.

68. Baurerdink R, Takei K, De Camilli P. Amphiphysin I is associated with coated endocytic intermediates and undergoes stimulation-dependent dephosphorylation in nerve terminals. J Biol Chem 1997;272:30984-30992.

69. Murinson BB, Guarnera JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008;71:1955-1958.

70. Graus F, Keime-Guibert F, Reeve R, Benyahia B, Ribhalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124(PT6):1138-1148.

71. Brieva-Ruiz L, Díaz-Hurtado M, Matías-Guiu X, Márquez-Medina D, Tarragó J, Graus F. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study. Clin Neuropathol 2008;37:1044-1046.

72. Chan KH, Veraino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001;50:301-311.

73. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931-1937.

74. Rojas I, Graus F, Keime-Guibert F, René R, Delattre JY, Ramón JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000;55:713-715.

75. Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsimouida I, Carlson NG. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol 2010;69:997-1007.

76. Vernino S, Lennon VA. New Purkinje cell kinase antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000;47:297-305.

77. Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003;54:38-50.

78. Hampton CW, Galperin D, Alvarez E, West MS. Encephalomyeloneuropathy with CRMP-5 antibodies in a patient with a primary mediastinal serinoma. Neuroimmunol Inflamm 2015;2:e82.

79. Nakae Y, Ikeda S, Yamamoto R, Tanaka F, Jokukura K. Hemichorea in a thymoma patient without anti-CRMP-5 antibody. Neurol Sci 2014;35:629-630.

80. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004;127(PT8):1831-1844.

81. Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol 2015;22:1151-1161.

82. Clowe ME, Behera MA, Anders CK, Copland S, Coffman CJ, Lepert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18:311-319.

83. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54:899-904.

84. Titulaer MJ, McCracken L, Gabilondo I, Arangüe T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcomes in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157-165.

85. Leyboldt F, Titulaer MJ, Aguilar E, Walther J, Bönnstrup M, Have meister S, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology 2013;81:1637-1639.

86. Chow FC, Glaser CA, Sheriff H, Xia D, Messenger S, Whitney R, et al. Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics. Clin Infect Dis 2015;60:1377-1383.

87. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis 2010;37:534-541.

88. Chancey C, Griene A, Volkova E, Rios M. The global ecology and epidemiology of West Nile virus. Biomed Res Int 2015;2015:376280.

89. DeLone DR, Goldstein RA, Petermann G, Salamat MS, Miles JM, Knechtle SJ, et al. Disseminated aspergillosis involving the brain: distribution and imaging characteristics. AJNR Am J Neuroradiol 1999;20:1597-1604.